Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Affymax Inc. stock logo
AFFY
Affymax
$0.00
+14.3%
$0.00
$0.00
$0.00
N/A7.342,819 shs25,030 shs
AOLS
Aeolus Pharmaceuticals
$0.00
$0.00
$0.01
N/A1.2835 shsN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$17.06
$17.06
$2.13
$18.00
$834.46MN/A11,851 shs39 shs
89BIO stock logo
ETNB
89BIO
$11.00
+2.0%
$9.51
$4.16
$11.84
$1.57B1.281.53 million shs1.44 million shs
MYRX
Myrexis
$0.00
$0.00
$0.00
$0.01
N/A0.6313 shsN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Affymax Inc. stock logo
AFFY
Affymax
-12.50%-12.50%-12.50%-12.50%0.00%
AOLS
Aeolus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00%0.00%0.00%0.00%0.00%
89BIO stock logo
ETNB
89BIO
+2.08%+6.31%+4.86%+94.94%+24.62%
MYRX
Myrexis
0.00%0.00%+100.00%-97.14%-96.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
1.6226 of 5 stars
3.51.00.00.01.10.80.6
MYRX
Myrexis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Affymax Inc. stock logo
AFFY
Affymax
0.00
N/AN/AN/A
AOLS
Aeolus Pharmaceuticals
0.00
N/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00
N/AN/AN/A
89BIO stock logo
ETNB
89BIO
3.00
Buy$26.43140.26% Upside
MYRX
Myrexis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MYRX, ETNB, CXRXF, AOLS, and AFFY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
6/11/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/10/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/30/2025
89BIO stock logo
ETNB
89BIO
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$525.58M1.59N/AN/A$0.16 per share106.63
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/A$3.34 per shareN/A
MYRX
Myrexis
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Affymax Inc. stock logo
AFFY
Affymax
N/AN/A0.00N/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
-$74.86MN/AN/AN/A-15.31%N/A-4.38%N/A
89BIO stock logo
ETNB
89BIO
-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)
MYRX
Myrexis
N/AN/A0.00N/AN/AN/AN/AN/A

Latest MYRX, ETNB, CXRXF, AOLS, and AFFY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
89BIO stock logo
ETNB
89BIO
-$0.49N/AN/AN/AN/AN/A
5/1/2025Q1 2025
89BIO stock logo
ETNB
89BIO
-$0.50-$0.49+$0.01-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/AN/A
MYRX
Myrexis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
257.04
2.39
1.61
89BIO stock logo
ETNB
89BIO
0.06
18.03
18.03
MYRX
Myrexis
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Affymax Inc. stock logo
AFFY
Affymax
N/A
AOLS
Aeolus Pharmaceuticals
N/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
89BIO stock logo
ETNB
89BIO
N/A
MYRX
Myrexis
N/A

Insider Ownership

CompanyInsider Ownership
Affymax Inc. stock logo
AFFY
Affymax
1.55%
AOLS
Aeolus Pharmaceuticals
66.60%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
89BIO stock logo
ETNB
89BIO
2.60%
MYRX
Myrexis
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Affymax Inc. stock logo
AFFY
Affymax
4N/AN/ANot Optionable
AOLS
Aeolus Pharmaceuticals
4N/AN/ANot Optionable
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
42948.91 millionN/ANot Optionable
89BIO stock logo
ETNB
89BIO
40145.98 million142.19 millionOptionable
MYRX
Myrexis
1N/AN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Affymax stock logo

Affymax OTCMKTS:AFFY

$0.0008 +0.00 (+14.29%)
As of 11:28 AM Eastern

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Aeolus Pharmaceuticals OTCMKTS:AOLS

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

ADVANZ PHARMA stock logo

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)
As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

89BIO stock logo

89BIO NASDAQ:ETNB

$11.00 +0.22 (+2.04%)
Closing price 04:00 PM Eastern
Extended Trading
$11.34 +0.34 (+3.05%)
As of 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Myrexis OTCMKTS:MYRX

$0.0002 0.00 (0.00%)
As of 07/9/2025

Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.